We came across a bullish thesis on Halozyme Therapeutics, Inc. on 24K Research’s Substack. In this article, we will summarize the bulls’ thesis on HALO. Halozyme Therapeutics, Inc.'s share was trading at $70.98 as of February 20th. HALO’s trailing and forward P/E were 16.41 and 8.19, respectively according to Yahoo Finance. Morgan Stanley Lifted GE HealthCare Target to $80 in Late October, Citing Strong Orders and Backlog Wichy/Shutterstock.com Halozyme Therapeutics Inc (HALO), based in San Diego, Calif ...